Iridian Asset Management LLC Eagle Pharmaceuticals, Inc. Transaction History

Iridian Asset Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 07, 2019	SELL	$36.72 - $67.73 $34.3 Million - $63.4 Million	-935,398 Closed	0 $0
Q3 2018 Nov 09, 2018	BUY	$66.65 - $83.86 $4.96 Million - $6.25 Million	74,487 Added 8.65%	935,398 $64.9 Million
Q2 2018 Aug 01, 2018	SELL	$51.25 - $76.62 $626,275 - $936,296	-12,220 Reduced 1.4%	860,911 $65.1 Million
Q1 2018 May 10, 2018	SELL	$52.16 - $66.86 $1.49 Million - $1.91 Million	-28,566 Reduced 3.17%	873,131 $46 Million
Q4 2017 Feb 01, 2018	BUY	$49.6 - $60.87 $4.34 Million - $5.33 Million	87,483 Added 10.74%	901,697 $48.2 Million
Q3 2017 Nov 08, 2017	BUY	$46.62 - $60.36 $5.56 Million - $7.2 Million	119,327 Added 17.17%	814,214 $48.6 Million
Q2 2017 Aug 07, 2017	BUY	N/A	694,887	694,887 $54.8 Million

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Iridian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Iridian Asset Management LLC with notifications on news.